Successful methods of combating acute respiratory viral infections and influenza were discussed at a conference in Kazan
According to Rospotrebnadzor 1 , the incidence of acute respiratory viral infections and influenza has increased by 7.7% over the past week, with rates exceeding averages in 49 regions of Russia. In 30 regions of the Russian Federation, the number of hospitalizations has increased by 30% compared to the previous week.
Given the diversity of respiratory viruses, treatment of infectious diseases requires a comprehensive approach.
As noted by Olesya Valeryevna Skorokhodkina , MD, Professor, Head of the Department of Clinical Immunology with Allergology of the Federal State Budgetary Educational Institution of Higher Education Kazan State Medical University: “During the season of colds and viral infections, it is important to choose drugs with a known cellular mechanism of action and proven immunotropic activity. For example, azoximer bromide (Polyoxidonium®) enhances the synthesis of interferons and activates natural killers (NK cells 2 ), which play a key role in the fight against viruses.”
Intoxication is one of the typical problems with ARVI and flu. It manifests itself as fever, headache, weakness and can lead to serious complications.
Studies show that azoximer bromide, due to its high-molecular nature, forms complexes with toxin molecules and removes them from the body, and also suppresses the formation of neutrophil extracellular traps, which helps reduce intoxication and inflammation 3,4,5,6 . Such data were presented by Mikhail Petrovich Kostinov , Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Head of the Laboratory of Vaccine Prevention and Immunotherapy of the I.I. Mechnikov Research Institute of Vaccines and Serums.
Children suffer from acute respiratory viral infections 2.7–3.2 times more often than adults 7 . A meta-analysis of 5 studies involving 542 children aged 3 to 18 years 8 presented at the conference demonstrated that azoximer bromide in the complex treatment of respiratory infections helps reduce the severity of the infectious and inflammatory process and has a positive effect on immune mechanisms.
Experts noted that Polyoxidonium® in the form of a solution for intranasal or sublingual (under the tongue) use is approved for use in children from 6 months 9 .
Particular attention was paid to the role of mucosal immunity, the first barrier to viruses and bacteria.
"Many chronic diseases begin with damage to the ENT organs. If mucosal immunity does not work normally, chronic rhinosinusitis can lead to the development of bronchial asthma; tonsillitis - to rheumatism and cardiovascular diseases," emphasized Irina Mikhailovna Kirichenko , MD, professor, head of the otolaryngology center.
Activation of mucosal immunity plays an important role in the prevention and treatment of ARVI. Azoximer bromide helps to stimulate mucosal immunity, enhancing the body's defenses. A study involving more than 16,000 patients showed 10 that the use of Polyoxidonium as part of a comprehensive treatment for ENT diseases allows for the rapid relief of ARVI symptoms such as fever, sore throat, nasal congestion, and cough.
Reference information
Polyoxidonium® (azoximer bromide) is an original Russian drug from Petrovax Pharm, widely used in clinical practice in Russia and abroad. It is used in the complex therapy of acute respiratory viral infections and ENT diseases in adults and children from 6 months. Polyoxidonium with polyeffect® helps to cope with the infection at the source of infection - on the mucous membrane of the nasopharynx, accelerating the elimination of catarrhal phenomena, and eliminates viral intoxication, improving well-being from the first days of treatment.
Advertisement. OOO NPO PETROVAKS PHARM. https://polyoxidonium.ru/ erid: F7NfYUJCUneRGydsmQE9
1. https://rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=29409
2. NK cells – natural killers, a special type of lymphocyte that plays a key role in innate immunity.
3. Dagil Yu., Pinegin B.V., et al. Effect of azoximer bromide on the formation of neutrophil traps. // RMZh, Immune Response, No. 1 (2), pp. 42-46
4. Dyakonova VA et al. Int. Immunopharmac. 2004
5. Kuznetsova I. V. and Rashidov T. N. “The Place of Immunomodulators in the Treatment of Inflammatory Diseases of the Pelvic Organs.” Gynecology 18, no. 5 (2016): 26–31.
6. Nekrasov A.V., Puchkova N.G. and Ivanova A.S. “Chemical aspects of the creation of Polyoxidonium.” Immunology, vol. 5 (2000): 19–23.
7. Aleksandrovich Yu. S. Acute respiratory infections in children. Complications and life-threatening conditions. Study guide. http://www.labirint.ru/books/828483/ .
8. Karaulov A. V., Gorelov A. V. Use of azoximer bromide in the treatment of infectious and inflammatory diseases of the respiratory system in children: a meta-analysis of controlled clinical trials. Journal of Infectology, Vol. 11, No. 4, 2019. pp. 31-41
9. “Instructions for medical use of the medicinal product Polyoxidonium, solution for injection and local use LP-005312”, July 20, 2021 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=79ae0a13-d997-4177-8bba-546cd049858d&t= .
10. Svistushkin Valery Mikhailovich, Nikiforova Galina Nikolaevna, Eremeeva Ksenia Vladimirovna, Dekhanov Artem Sergeevich, and Kochetkov Petr Aleksandrovich. "Possibilities of Azoximer Bromide in the Treatment of Patients with Acute Infectious and Inflammatory Diseases of the Upper Respiratory Tract." Therapeutic Archives 95, no. 11 (December 22, 2023): 951–57. https://doi.org/10.26442/00403660.2023.11.202488
medportal ru
